

**BAXTER INTERNATIONAL INC.**  
**Key Product Line Sales**  
**Periods Ending March 31, 2008 and 2007**  
**(unaudited)**  
**(\$ in millions)**

	Q1 2008	Q1 2007	% Growth @ Actual Rates	% Growth @ Constant Rates
<b>BioScience</b>				
Recombinants	\$436	\$388	12%	8%
Plasma Proteins	260	225	16%	10%
Antibody Therapy	286	222	29%	25%
Regenerative Medicine <sup>1</sup>	94	82	15%	10%
Other <sup>2</sup>	134	155	(14%)	(22%)
<b>Total BioScience<sup>3</sup></b>	<b>\$1,210</b>	<b>\$1,072</b>	<b>13%</b>	<b>8%</b>
<b>Medication Delivery</b>				
IV Therapies	\$371	\$320	16%	8%
Global Injectables	368	361	2%	(2%)
Infusion Systems	220	209	5%	1%
Anesthesia	99	89	11%	7%
Other	7	11	(36%)	(36%)
<b>Total Medication Delivery</b>	<b>\$1,065</b>	<b>\$990</b>	<b>8%</b>	<b>2%</b>
<b>Renal</b>				
PD Therapy	\$445	\$419	6%	(1%)
HD Therapy	113	106	7%	(2%)
<b>Total Renal</b>	<b>\$558</b>	<b>\$525</b>	<b>6%</b>	<b>(2%)</b>
<b>Baxter excluding Transfusion Therapies</b>	<b>\$2,833</b>	<b>\$2,587</b>	<b>10%</b>	<b>4%</b>
<b>Transfusion Therapies<sup>4</sup></b>	<b>\$44</b>	<b>\$88</b>	<b>(50%)</b>	<b>(51%)</b>
<b>TOTAL BAXTER</b>	<b>\$2,877</b>	<b>\$2,675</b>	<b>8%</b>	<b>2%</b>

1 Previously referred to as BioSurgery.

2 Principally includes vaccines, sales of plasma to third parties, and recombinant FIX (BeneFIX). Sales of BeneFIX ceased as of June 30, 2007.

3 Prior year BioScience sales data has been reclassified as described in Note 4.

4 The TT business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. The TT totals above include sales of TT products through the date of divestiture, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.